Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1Thoracic 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Pancreatic Neoplasms 2Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × cabiralizumab × Gastrointestinal × Clear all
NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

NYU Langone Health

Phase 2 Terminated
13 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

University of California, San Diego

Phase 2 Completed
2 enrolled 10 charts
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03599362 2021-10-19

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

NYU Langone Health

Phase 2 Terminated
7 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡